Healthcare company Nuvo Pharmaceuticals Inc (TSX:NRI) (OTCQX:NRIFF) disclosed on Friday that it recorded a net income from continuing operations of USD1.6m for the year ended 31 December 2017.

This marks a decline in earnings when compared with net income from continuing operations of USD7.4m for the year ended December 31, 2016

Total revenue of USD17.5m was collected for the year ended 31 December 2017, down over total revenue of USD27.0m for the comparative year.

R&D expenses of USD0.6m were recorded for the year ended 31 December 2017 , a dip from R&D of USD1.4m for the comparative year.

Adjusted EBITDA of USD2.2m was announced for the year ended 31 December 2017, a fall versus Adjusted EBITDA of USD8.9m for the comparative year.